Terumo Corporation · TSE:4543
Terumo — Investor Presentation (August 2010)
9 slides from Terumo's investor presentation, Aug 5, 2010
Slide 1: Start of New Management
Start of New Management Terumo Corporation Representative Director & President Yutaro Shintaku August 5, 2010 1
Slide 2: Essential Agenda for the Initial 100 Days
Essential Agenda for the Initial 100 Days 1. Communication 2. Activate the growth strategy 2
Slide 3: 1. Communication: New management policy
1. Communication New management policy ¾ Evolution of management: Speed and Global focus ¾ Acceleration of growth strategies: Region and Business ¾ Japanese business development in new direction ¾ Company growth = People growth Face to face dialogue with employees; a sense of the field Distrib
Slide 4: 2. Activate the Growth Strategy: Region
2. Activate the Growth Strategy: Region Strengthening the China strategy ¾ From export/import to local manufacturing and distribution ¾ Negotiation ongoing for partnership with local company Strengthening business in other emerging countries ¾ Assign the very top key official ¾ Hire local execut
Slide 5: 2. Activate the growth strategy: Business
2. Activate the growth strategy: Business 1) Value added drug delivery devices catered for biomedicine (Drug & Device) 2) Global diabetes management business 3) Transfusion as a basic healthcare infrastructure 4) Further expansion of the minimally invasive procedures 5) Growth of Left Ventricular As
Slide 6: 1) Value Added Drug Delivery Devices Catered for Biomedicine (Drug & Device)
1) Value Added Drug Delivery Devices Catered for Biomedicine (Drug & Device) Synthetic medicine Biomedicine Oral administration Injection Biomedicine market $120 billion -> 200 billion in ten years Growing Growingdemands demandsof ofvalue valueadded addeddrug drugdelivery deliverydevice device cater
Slide 7: Business Model of Global Drug & Device
Business Model of Global Drug & Device ”NESP Plastic Syringe”: Remedy for renal anemia Safe, Value Plastic Syringe <Additionally approved> Easy to use Added application for conservative treatment & Reduced NESP Subcutaneous injection frequency dose Improve patients’ QOL and efficiency of the medical
Slide 8: New Administration Device for Influenza Vaccines
New Administration Device for Influenza Vaccines - Enhance the efficacy: 5 fold - Application for self-injection Epidermis Dermis Subcutaneous tissue Immunity Adopted for the subsidy project of the Muscle Intra dermal “Special Subsidy for Improvement of Current administration Development and Product
Slide 9: IR Contact
IR Contact TERUMO Corporation Corporate Communication (IR) Dept. E-mail: kouhou_terumo01@terumo.co.jp Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo